BCDA-04

N/A

Report date: 2025/07/14 16:28:53

Base Information

Drug NameBCDA-04

Drug Alias NamePulmALLO cell therapy (BioCardia)BCDA-04

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic

Mechanisms of ActionNeurokinin 1 receptor modulators

TargetsNeurokinin 1 receptor

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesBiocardia Inc

China Registration ClassN/A

Develop Information

Active CompaniesBiocardia Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult

Inactive IndicationsN/A

Other Information

ATC CodeN/A